The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

There are many problems with the plan. It ignores the fact, for instance, that generic drugs, which make up 90% of ...

On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD ...

The order calls on the health department, led by Robert F. Kennedy Jr., to broker new price tags for drugs over the next ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...